Alpine Global Management’s Lyell Immunopharma LYEL Stock Holding History

Alpine Global Management’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,353	Closed	-$94K	–	307
2022 Q4	$94K	Buy	+1,353	New	+$134K	0.03%	278
2022 Q1	–	Sell	-588	Closed	-$91K	–	599
2021 Q4	$91K	Buy	+588	New	+$131K	0.01%	674

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Alpine Global Management's LYEL Position: Q1 2023 in Review

Alpine Global Management sold out of Lyell Immunopharma (LYEL) in Q1 2023, closing a stake of 1,353 shares — an estimated $94K sold.

Alpine Global Management first reported a position in LYEL in Q4 2021 and held it in 2 quarters. The position peaked at $94K in Q4 2022. 99 funds tracked by Wall St. Rank hold LYEL as of Q1 2023.

Alpine Global Management reported no remaining Lyell Immunopharma position as of Q1 2023 after selling out during the quarter.
Alpine Global Management sold 1,353 Lyell Immunopharma shares in Q1 2023, an estimated $94K.
Alpine Global Management first reported a position in Lyell Immunopharma in Q4 2021 and held it in 2 quarters.
Alpine Global Management's Lyell Immunopharma position peaked at $94K in Q4 2022.
99 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.